Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and acts as a substrate for cellular metabolism, replenishing glucose stores. Sodium chloride provides electrolytes for maintenance of osmotic pressure and fluid balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Intravenous rehydration and maintenance of fluid and electrolyte balance,Provision of calories in parenteral nutrition,Treatment of dehydration,Vehicle for drug administration
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous; adult dose is 500-1000 m L at a rate of 100-200 m L/hour; frequency depends on fluid and electrolyte needs; maximum rate up to 400 m L/hour in hypovolemic states.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Not applicable as a terminal half-life; dextrose is rapidly cleared from circulation with a metabolic clearance rate of ~15-20 mg/kg/min under normal conditions. The half-life of infused glucose is approximately 15-30 minutes due to rapid cellular uptake and metabolism.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the tricarboxylic acid cycle. Sodium chloride is not metabolized but excreted primarily by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle; essentially eliminated as CO₂ (exhaled) and water (renal, insensible loss). Sodium and chloride are primarily excreted renally (95%) with minor fecal (<2%) and sweat losses.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Negligible (<1%); dextrose does not bind to plasma proteins. Sodium and chloride are not protein bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose distributes into total body water (~0.55 L/kg). Sodium distributes primarily in extracellular fluid (~0.2 L/kg). Volume of distribution for dextrose and electrolytes is not clinically meaningful as a single value.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100%. Oral dextrose: variable but high; not applicable for this formulation, which is IV only. Sodium chloride is completely bioavailable via IV.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
For GFR <30 m L/min/1.73 m²: reduce infusion rate to 50-100 m L/hour; monitor serum sodium and glucose; avoid in anuria.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of fluid overload and hyperglycemia.
No dosage adjustment required for hepatic impairment.
Intravenous; weight-based dose: 5-10 m L/kg; infusion rate: 2-6 m L/kg/hour; adjust based on age, weight, and clinical status; maximum 100 m L/kg/day in term neonates.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Elderly: use lowest effective dose; infusion rate: 50-100 m L/hour; monitor for fluid overload, hyperglycemia, and electrolyte imbalance due to decreased renal and cardiac function.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Not applicable; no FDA black box warning for this combination product.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Monitor serum glucose and electrolytes, especially in patients with diabetes mellitus or renal impairment,Avoid use in patients with known hypersensitivity to corn or corn products,Risk of fluid overload in patients with heart failure or renal insufficiency,Use with caution in patients with hyperglycemia, hyponatremia, or hypernatremia,Do not administer simultaneously with blood products
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia,Hypernatremia,Hypersensitivity to dextrose or sodium chloride,Patients with known allergy to corn
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No significant food interactions; however, dietary sodium intake should be considered in patients with hypertension or edema.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Dextrose 5% and sodium chloride 0.225% is considered compatible in pregnancy when used as a vehicle or for correction of fluid and electrolyte disturbances. No teratogenic effects are expected at standard infusion rates. However, excessive administration may cause maternal hyperglycemia, which can lead to fetal hyperinsulinism and neonatal hypoglycemia. No known structural teratogenicity.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Dextrose and sodium chloride are normal constituents of breast milk. Infusion of this solution does not pose a risk to the nursing infant. No M/P ratio data available; both components are naturally present in human milk.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy induces increased plasma volume and glomerular filtration rate, which may require higher infusion rates to achieve desired correction. However, standard dosing is typically adequate; adjust based on clinical response and serum electrolyte monitoring.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Use cautiously in pediatric and elderly patients to avoid fluid overload and electrolyte imbalance. Monitor serum sodium, glucose, and osmolarity in patients with renal impairment or hyperglycemia. Do not administer if solution is discolored or contains particulates.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Report signs of fluid overload (swelling, rapid weight gain, shortness of breath).,Advise patients with diabetes that this solution contains dextrose and may affect blood glucose levels.,Inform patients that intravenous administration requires careful monitoring by healthcare professionals.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.225% vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is a Electrolyte that works by Dextrose provides a source of calories and acts as a substrate for cellular metabolism, replenishing glucose stores. Sodium chloride provides electrolytes for maintenance of osmotic pressure and fluid balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.225% and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is: Intravenous; adult dose is 500-1000 m L at a rate of 100-200 m L/hour; frequency depends on fluid and electrolyte needs; maximum rate up to 400 m L/hour in hypovolemic states.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.225% and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is classified as Category A/B. Dextrose 5% and sodium chloride 0.225% is considered compatible in pregnancy when used as a vehicle or for correction of fluid and electrolyte disturbances. No teratogenic effects . AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.